胸腔内注射不同药物治疗肺癌胸腔积液疗效对比观察研究

A Comparative Study on the Therapeutic Effect of Different Drugs Injected into the Chest Cavity in the Treatment of Pleural Effusion of Lung Cancer

目的比较胸腔内注射贝伐单抗、顺铂治疗肺癌胸腔积液的效果差异。方法纳入我院确诊的60例肺癌胸腔积液患者为研究对象,研究时间自2018年6月至2019年6月,根据使用药物不同随机分两组:贝伐单抗组、顺铂组。对比两种药物的治疗效果。结果贝伐单抗组治疗总缓解率70.0%更高于顺铂组的缓解率40.0%(P<0.05);贝伐单抗组患者除恶心呕吐、皮疹发生率比顺铂组高(P<0.05),在其它用药不良反应上皆无很大差异(P>0.05)。结论使用贝伐单抗作为胸腔内注射药物治疗肺癌胸腔积液,较顺铂的使用效果更高,且用药安全性较佳。

Objective To compare the efficacy of bevacizumab and cisplatin in the treatment of pleural effusion of lung cancer.Methods 60 patients with lung cancer and pleural effusion diagnosed in our hospital were included in the study.The study period was from June 2018 to June 2019.According to the different drugs used,they were randomly divided into two groups:Bevacizumab group and cisplatin group.The therapeutic effects of the two drugs were compared.Results The total remission rate of bevacizumab group was 70.0%,higher than that of cisplatin group(40.0%)(P<0.05);the incidence of nausea,vomiting and rash in bevacizumab group was higher than that of cisplatin group(P<0.05),and there was no significant difference in other adverse reactions(P>0.05).Conclusion Bevacizumab is more effective and safe than cisplatin in the treatment of pleural effusion of lung cancer.